Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology
Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.
FDA approval of IDVYNSO gives Merck a fresh HIV story, but will clinicians switch stable patients?
Merck’s IDVYNSO has won FDA approval in HIV. Read what the new two-drug regimen changes, where it fits, and what risks still matter.